Cell line access to revolutionize the biosimilars market

Area of Science:

• Pharmaceutical Economics
• Biotechnology
• Regulatory Science

Background:

• Biologic drugs are characterized by high manufacturing costs and prices.
• Biosimilars, while less expensive than originator biologics, remain costly.
• Current biosimilar pricing is influenced by extensive reverse-engineering and clinical trials.

Purpose of the Study:

• To analyze the cost of biologic drug production versus market prices.
• To propose a novel regulatory framework to reduce biosimilar development costs.
• To explore mechanisms for achieving significant price reductions for biologics post-patent expiry.

Main Methods:

• Analysis of biologic drug production costs in high-income countries and India.
• Evaluation of the economic impact of reverse-engineering and Phase 3 trials for biosimilars.
• Proposal for regulatory submission of originator cell line stocks and manufacturing process details.

Main Results:

• Manufacturing costs for biologics are often less than 10% of their price in high-income countries.
• Biosimilar prices in India are less than a third of originator biologic prices.
• The proposed system could substantially decrease investment for non-originator biologic development.

Conclusions:

• Current biosimilar pricing reflects high development costs, not solely manufacturing expenses.
• Regulatory sharing of originator manufacturing data can significantly lower barriers for biosimilar entry.
• This approach can facilitate greater price reductions for biologics, balancing access and innovation incentives.